Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 1

2(28.6%)

Phase 2

1(14.3%)

7Total

N/A(4)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00621218Phase 2Completed

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

Role: lead

NCT00643630Not ApplicableCompleted

Evaluation of Tetrix Cream as a Protective Barrier Against Injurious Materials

Role: lead

NCT00643214Not ApplicableCompleted

Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis

Role: lead

NCT00646867Not ApplicableCompleted

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

Role: lead

NCT00603772Phase 1Completed

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

Role: lead

NCT00604032Phase 1Completed

Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

Role: lead

NCT00644436Not ApplicableCompleted

Study to Determine if Tetrix Cream is Removed From the Hands by Gentle Washing With Soap and Water

Role: lead

All 7 trials loaded